Andrew Sumarsono1,2, Hussain Lalani1, Matthew W Segar1, Shreya Rao3, Muthiah Vaduganathan4, Rishi K Wadhera5, Sandeep R Das3, Ann Marie Navar3, Gregg C Fonarow6, Ambarish Pandey3. 1. Department of Internal Medicine (A.S., H.L., M.W.S.), University of Texas Southwestern Medical Center, Dallas. 2. Division of Hospital Medicine, Parkland Memorial Hospital, Dallas, TX (A.S.). 3. Division of Cardiology (S.R., S.R.D., A.M.N., A.P.), University of Texas Southwestern Medical Center, Dallas. 4. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.V.). 5. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (R.K.W.). 6. Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, CA (G.C.F.).
Abstract
BACKGROUND: The Affordable Care Act expanded Medicaid eligibility allowing low-income individuals greater access to health care. However, the uptake of state Medicaid expansion has been variable. It remains unclear how the Medicaid expansion was associated with the temporal trends in use of evidence-based cardiovascular drugs. METHODS: We used the publicly available Medicaid Drug Utilization and Current Population Survey to extract filled prescription rates per 1000 Medicaid beneficiaries of statins, antihypertensives, P2Y12 inhibitors, and direct oral anticoagulants. We defined expander states as those who expanded Medicaid on or before January 1, 2014, and nonexpander states as those who had not expanded by December 31, 2018. Difference-in-differences (DID) analyses were performed to compare the association of the Medicaid expansion with per-capita cardiovascular drug prescription rates in expander versus nonexpander states. RESULTS: Between 2011 and 2018, the total number of prescriptions among all Medicaid beneficiaries increased, with gains of 89.7% in statins (11.0 to 20.8 million), 76% in antihypertensives (35.3 to 62.2 million), and 37% in P2Y12 inhibitors (1.7 to 2.3 million). Medicaid expansion was associated with significantly greater increases in quarterly prescriptions (per 1000 Medicaid beneficiaries) of statins (DID estimate [95% CI]: 22.5 [16.5-28.6], P<0.001), antihypertensives (DID estimate [95% CI]: 63.2 [47.3-79.1], P<0.001), and P2Y12 inhibitors (DID estimate [95% CI]: 1.7 [1.2-2.2], P<0.001). Between 2013 and 2018, >75% of the expander states had increases in prescription rates of both statins and antihypertensives. In contrast, 44% of nonexpander states saw declines in statins and antihypertensives. The Medicaid expansion was not associated with higher direct oral anticoagulants prescription rates (DID estimate [95% CI] 0.9 [-0.3 to 2.1], P=0.142). CONCLUSIONS: The 2014 Medicaid expansion was associated with a significant increase in per-capita utilization of cardiovascular prescription drugs among Medicaid beneficiaries. These gains in utilization may contribute to long-term cardiovascular benefits to lower-income and previously underinsured populations.
BACKGROUND: The Affordable Care Act expanded Medicaid eligibility allowing low-income individuals greater access to health care. However, the uptake of state Medicaid expansion has been variable. It remains unclear how the Medicaid expansion was associated with the temporal trends in use of evidence-based cardiovascular drugs. METHODS: We used the publicly available Medicaid Drug Utilization and Current Population Survey to extract filled prescription rates per 1000 Medicaid beneficiaries of statins, antihypertensives, P2Y12 inhibitors, and direct oral anticoagulants. We defined expander states as those who expanded Medicaid on or before January 1, 2014, and nonexpander states as those who had not expanded by December 31, 2018. Difference-in-differences (DID) analyses were performed to compare the association of the Medicaid expansion with per-capita cardiovascular drug prescription rates in expander versus nonexpander states. RESULTS: Between 2011 and 2018, the total number of prescriptions among all Medicaid beneficiaries increased, with gains of 89.7% in statins (11.0 to 20.8 million), 76% in antihypertensives (35.3 to 62.2 million), and 37% in P2Y12 inhibitors (1.7 to 2.3 million). Medicaid expansion was associated with significantly greater increases in quarterly prescriptions (per 1000 Medicaid beneficiaries) of statins (DID estimate [95% CI]: 22.5 [16.5-28.6], P<0.001), antihypertensives (DID estimate [95% CI]: 63.2 [47.3-79.1], P<0.001), and P2Y12 inhibitors (DID estimate [95% CI]: 1.7 [1.2-2.2], P<0.001). Between 2013 and 2018, >75% of the expander states had increases in prescription rates of both statins and antihypertensives. In contrast, 44% of nonexpander states saw declines in statins and antihypertensives. The Medicaid expansion was not associated with higher direct oral anticoagulants prescription rates (DID estimate [95% CI] 0.9 [-0.3 to 2.1], P=0.142). CONCLUSIONS: The 2014 Medicaid expansion was associated with a significant increase in per-capita utilization of cardiovascular prescription drugs among Medicaid beneficiaries. These gains in utilization may contribute to long-term cardiovascular benefits to lower-income and previously underinsured populations.
Entities:
Keywords:
anticoagulant; drug prescription; drug utilization; medicaid; risk factor
Authors: Benjamin D Sommers; Bethany Maylone; Robert J Blendon; E John Orav; Arnold M Epstein Journal: Health Aff (Millwood) Date: 2017-05-17 Impact factor: 6.301
Authors: Erica L Brooks; Sarah Rosner Preis; Shih-Jen Hwang; Joanne M Murabito; Emelia J Benjamin; Margaret Kelly-Hayes; Paul Sorlie; Daniel Levy Journal: Am J Med Date: 2010-08 Impact factor: 4.965
Authors: Rishi K Wadhera; Deepak L Bhatt; Tracy Y Wang; Di Lu; Joseph Lucas; Jose F Figueroa; Kirk N Garratt; Robert W Yeh; Karen E Joynt Maddox Journal: JAMA Cardiol Date: 2019-02-01 Impact factor: 14.676
Authors: Emily M Bucholz; Angie Mae Rodday; Katherine Kolor; Muin J Khoury; Sarah D de Ferranti Journal: Circulation Date: 2018-03-26 Impact factor: 29.690
Authors: Andrew Sumarsono; Leo F Buckley; Sara R Machado; Rishi K Wadhera; Haider J Warraich; Rishi J Desai; Brendan M Everett; Darren K McGuire; Gregg C Fonarow; Javed Butler; Ambarish Pandey; Muthiah Vaduganathan Journal: Diabetes Care Date: 2020-09-04 Impact factor: 19.112
Authors: Rebecca Thorsness; Shailender Swaminathan; Yoojin Lee; Benjamin D Sommers; Rajnish Mehrotra; Kevin H Nguyen; Daeho Kim; Maricruz Rivera-Hernandez; Amal N Trivedi Journal: J Am Soc Nephrol Date: 2021-04-01 Impact factor: 14.978
Authors: Gabriel S Tajeu; Calvin L Colvin; Shakia T Hardy; Adam P Bress; Bamba Gaye; Byron C Jaeger; Gbenga Ogedegbe; Swati Sakhuja; Mario Sims; Daichi Shimbo; Emily C O'Brien; Tanya M Spruill; Paul Muntner Journal: PLoS One Date: 2022-08-05 Impact factor: 3.752